Stuttgart
18.09.26 | 21:56
0,825 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Advicenne Reports First Half Financial Results as of June 30, 2026, and Updates on Its Activities | 305 | Business Wire | Sibnayal end-market sales (Europe and Middle East) up 27% to €6.6 million, with royalties received increasing 45% to €0.54 million. Positive half-year net result of €4.6 million, compared... ► Artikel lesen | |
| 31.08. | Kurseinbruch bei Advicenne | 545 | Bernecker Börsenbriefe | Das französische Biopharma-Unternehmen hat den Zulassungsantrag bei der US-Gesundheitsbehörde FDA für das Medikament ADV7103 zur Behandlung der primären distalen renal-tubulären Azidose zurückgezogen.... ► Artikel lesen | |
| 31.08. | Advicenne decides to withdraw its ADV7103 New Drug Application in the USA | 416 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 20.07. | Advicenne Announces the Reimbursement of Sibnayal for the Treatment of dRTA in Spain | 394 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 16.07. | Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal and Likozam in France | 663 | Business Wire | The first half 2026 reported revenue is the first without the negative impact of early access rebates Reported revenue does not include royalties to be received from commercial partners... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 01.07. | Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal in the United Kingdom | 521 | Business Wire | Regulatory News:
Advicenne S.A. (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering... ► Artikel lesen | |
| 22.06. | Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million | 671 | Business Wire | The transaction reflects the commitment of key shareholders, such as Cemag Invest and Didier Laurens, Chairman and CEO, joined by Europe Offering and L1 Capital. Immediate funding of €1.4... ► Artikel lesen | |
| 01.06. | Advicenne Granted Reimbursement for Likozam in France and Sees Thereby Its Debt Reduced by Nearly €6 Million | 339 | Business Wire | Likozam will be reimbursed to patients starting June 12, 2026 Official reimbursement ends the "Early Access" clawback The price obtained offsets the discounts owed under the early... ► Artikel lesen | |
| 21.05. | Advicenne Announces Changes to Its Governance Following Its Annual General Meeting on May 21, 2026 | 499 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 -ALDVI), a pharmaceutical company specializing in the development and marketing of innovativetreatments for people suffering from... ► Artikel lesen | |
| 05.05. | Advicenne Announces the Opening of a Safeguard Proceedings to Restructure Its Financial Liabilities and Finalize the Extension of Its Cash Runway | 705 | Business Wire | A proactive initiative to restructure the Company's debt A protective framework that allows for the continuation of commercial, clinical, and regulatory activities, as well as discussions... ► Artikel lesen | |
| 24.04. | Advicenne 2025 Universal Registration Document Made Available | 462 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 26.03. | Advicenne Reports Its 2025 Annual Financial Results | 988 | Business Wire | Product sales up 18.7% to €5.8 million
European end-market sales of Sibnayal rose by more than 71% to nearly €11 million
Royalties doubled to over €1.1 million
Cash position... ► Artikel lesen | |
| 02.02. | Advicenne: Official Reimbursement of Sibnayal for the Treatment of dRTA in France | 894 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 27.01. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in UAE | 519 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 22.01. | Advicenne: 2025 Full Year Sales | 626 | Business Wire | 2025 sales totaled €5.73m, up 18.4%
Sibnayal sales rose 36.6% to €3.01m
2025 Royalties are estimated at €1m, double the amount for 2024
End-markets estimated sales of Sibnayal... ► Artikel lesen | |
| 20.01. | Advicenne: 2026 Financial Calendar | 542 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 19.01. | Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal in the United States for the Treatment of dRTA | 540 | Business Wire | The US regulatory agency has set the target date for the final approval decision, known as the PDUFA date, as of September 3rd, 2026.
Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746... ► Artikel lesen | |
| 12.01. | Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal in European Union | 441 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11.25 | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 625 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,090 | -1,94 % | Platzt der Knoten?: Bayer-Aktie vor dem wichtigsten Glyphosat-Termin der Unternehmensgeschichte? | © Foto: KI-generiert mit DALL-EVor fast 10 Jahren hat Bayer Monsanto übernommen. Damals hat wohl niemand in Leverkusen damit gerechnet, dass eine jahrelange Prozessflut damit verbunden ist. Biegt die... ► Artikel lesen | |
| PFIZER | 24,000 | -0,15 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| ABBVIE | 229,90 | +0,09 % | AbbVie reicht EU-Beihilfebeschwerde gegen Regelungen des GKV-Beitragssatzstabilisierungsgesetzes ein und warnt vor ungleichem Zugang zu innovativen Arzneimitteln | Wiesbaden (ots) - - AbbVie Deutschland hat eine Beschwerde eingereicht und die Europäische Kommission gebeten zu prüfen, ob die Regelungen des GKV-Beitragssatzstabilisierungsgesetzes zu wirkstoffübergreifenden... ► Artikel lesen | |
| ELI LILLY | 1.003,60 | +0,02 % | Novo Nordisk macht aus Wegovy immer mehr als ein Abnehm-Medikament - warum Big Pharma genau solche Plattformen sucht | ||
| MERCK & CO | 127,90 | +0,11 % | Dividendenbekanntmachungen (15.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AKVA GROUP ASA NO0003097503 1 NOK 0,0927 EUR ALEXANDRIA GROUP OYJ FI4000153465 - 0,35 EUR ALTRIA GROUP INC US02209S1033 1,11 USD 0... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 54,73 | -0,27 % | Neuer Pharma-Player: Anthropic geht heimlich ins Labor - der nächste große KI-Coup? | © Foto: Andrej Sokolow - dpaAnthropic drängt in die Biowissenschaften und baut dafür ein eigenes Labor auf. Der KI-Konzern will die Medikamentenentwicklung massiv beschleunigen Enthaltene Werte: US1101221083... ► Artikel lesen | |
| INNOCAN PHARMA | 1,475 | -1,01 % | InnoCan Pharma-Aktie im Check am 19.09. (10:58 Uhr): Meine aktuelle Lageeinschätzung | ||
| DOCMORRIS | 11,380 | +0,62 % | DocMorris: Finaler Wandlungspreis und Emissionsvolumen der Neuen Wandelanleihe mit Fälligkeit 2031 | Frauenfeld (www.anleihencheck.de) - DocMorris: Finaler Wandlungspreis und Emissionsvolumen der Neuen Wandelanleihe mit Fälligkeit 2031 - AnleihenewsAnbei eine aktuelle Pressemitteilung der DocMorris... ► Artikel lesen | |
| INCYTE | 109,15 | 0,00 % | Incyte auf Morgan Stanley Konferenz: Pipeline-Umbau gewinnt an Fahrt | ||
| SINOPHARM | 1,655 | +1,04 % | SINOPHARM (01099): ANNOUNCEMENT (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 15 SEPTEMBER 2026; AND (2) ELECTION OF CHAIRMAN ... | ||
| HALEON | 4,023 | +0,60 % | Haleon plc - 6-K, Report of foreign issuer | ||
| HAPPY BELLY FOOD GROUP | 0,940 | +1,62 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness QSR Secures Real Estate Location for Multi-Unit Franchisee in Kitchener, Ontario | Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| MERCK KGAA | 129,85 | -1,22 % | Merck strengthens commitment to China with rare disease awareness initiative | ||
| IM CANNABIS CORP | 4,200 | -0,71 % | IM Cannabis Stock Surges 247% | ||
| NOVO NORDISK | 37,580 | -0,12 % | Novo nordisk-Aktie im Check am 20.09. (10:55 Uhr): Meine aktuelle Lageeinschätzung |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.